The approval was based on data from an open-label phase 1/2 trial in patients aged 1 to 21 years that included 26 patients with relapsed or refractory, systemic ALK-positive ALCL after at least 1 systemic treatment.
An intense 2020 may be behind us, but, this year seems likely to place the COVID-19 pandemic front and center again.
Neutralizing antibodies detected in 90 percent or more of all participants on day 29 after the first vaccine dose.
Passengers without proof of a negative test will not be allowed to board flights to America
Similar in-person rules for other medications have been suspended during the pandemic
After six to 12 months of treatment with the drug, patients no longer had amyloid protein plaques.
Patients will be able to share information collected in the app with health care providers to provide a comprehensive assessment of the SCS or DRG therapy.
MPR highlights health innovations from the 2021 Consumer Electronics Show (CES).
Ligelizumab is a high-affinity monoclonal anti-immunoglobulin E (IgE) antibody.
Brilacidin is a first-in-class host defense protein mimetic.
Please login or register first to view this content.
